Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 7, 2026

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
08:38

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery

Published on: October 4, 2018

21.8K

Idelalisib.

Katja Zirlik1,2, Hendrik Veelken3

  • 1Department of Medicine I: Hematology, Oncology, and Stem Cell Transplantation, University Medical Center Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Value of NT-proBNP in Patients Treated With Allogeneic Stem Cell Transplantation.

JACC. Advances·2025
Same author

Transplantation strategy affects the risk of GvHD after prophylactic and preemptive donor lymphocyte infusion.

Annals of hematology·2025
Same author

Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.

Leukemia·2025
Same author

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.

Blood cancer journal·2025
Same author

Correction: Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion.

Frontiers in immunology·2025
Same author

MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis.

Haematologica·2025

Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, effectively targets B-cell leukemias and lymphomas. This review details idelalisib

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Idelalisib is a novel, orally bioavailable small-molecule inhibitor targeting the phosphoinositide 3-kinase delta (PI3Kδ) isoform.
  • PI3Kδ is selectively expressed in hematopoietic cells and plays a critical role in B-cell signaling pathways.
  • Aberrant PI3Kδ signaling is implicated in the pathogenesis of various B-cell malignancies.

Purpose of the Study:

  • To review the preclinical and clinical activity of idelalisib.
  • To focus on the clinical efficacy of idelalisib in chronic lymphocytic leukemia (CLL).
  • To provide an overview of idelalisib as the first approved PI3K inhibitor.

Main Methods:

  • Preclinical studies evaluating idelalisib's mechanism of action and in vitro/in vivo efficacy.
Keywords:
Chronic lymphocytic leukemia (CLL)IdelalisibKinase inhibitorPI 3 Kinase

Related Experiment Videos

Last Updated: Feb 7, 2026

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
08:38

Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery

Published on: October 4, 2018

21.8K
  • Clinical trials assessing idelalisib's safety, tolerability, and efficacy in patients with B-cell malignancies.
  • Review of published literature and clinical data on idelalisib.

    • Main Results:

    • Idelalisib demonstrated significant preclinical activity by inhibiting PI3Kδ and blocking B-cell survival pathways.
    • Clinical studies showed idelalisib's efficacy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL).
    • Idelalisib is the first PI3K inhibitor approved by the US FDA for specific hematologic malignancies.

    Conclusions:

    • Idelalisib represents a targeted therapy option for patients with relapsed/refractory CLL, FL, and SLL.
    • Inhibition of PI3Kδ by idelalisib offers a promising therapeutic strategy in B-cell malignancies.
    • Further research and clinical evaluation of idelalisib and similar agents are warranted.